[
  {
    "ts": null,
    "headline": "Ocular: 'Buy' As AXPAXLI Program For Wet-AMD Moves To Potential NDA Filing",
    "summary": "Ocular Therapeutix keeps a \"Buy\" rating on strong AXPAXLI SOL-1 wet-AMD phase 3 data and FDA/NDA catalysts ahead. Here's what you need to know.",
    "url": "https://finnhub.io/api/news?id=983b1b7b2718519dc6547b659bd16781de27ca394a5a722f6251e895316b9d8d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771335435,
      "headline": "Ocular: 'Buy' As AXPAXLI Program For Wet-AMD Moves To Potential NDA Filing",
      "id": 139125579,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253559091/image_2253559091.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Ocular Therapeutix keeps a \"Buy\" rating on strong AXPAXLI SOL-1 wet-AMD phase 3 data and FDA/NDA catalysts ahead. Here's what you need to know.",
      "url": "https://finnhub.io/api/news?id=983b1b7b2718519dc6547b659bd16781de27ca394a5a722f6251e895316b9d8d"
    }
  },
  {
    "ts": null,
    "headline": "Ocular Therapeutix stock news: Why positive data led to a 25% drop",
    "summary": "Investing.com -- Ocular Therapeutix (NASDAQ:OCUL) stock fell 25% Tuesday after the company reported top-line results from its Phase 3 SOL-1 superiority trial for Axpaxli in wet age-related macular degeneration (AMD). EyePoint (NASDAQ:EYPT) shares dropped 15%, while Regeneron Pharmaceuticals (NASDAQ:REGN) shares were flat.",
    "url": "https://finnhub.io/api/news?id=99046c8274aa789d04e09d8a21c51007ce952638b6c31812c698431afcdfc302",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771335034,
      "headline": "Ocular Therapeutix stock news: Why positive data led to a 25% drop",
      "id": 139122262,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Investing.com -- Ocular Therapeutix (NASDAQ:OCUL) stock fell 25% Tuesday after the company reported top-line results from its Phase 3 SOL-1 superiority trial for Axpaxli in wet age-related macular degeneration (AMD). EyePoint (NASDAQ:EYPT) shares dropped 15%, while Regeneron Pharmaceuticals (NASDAQ:REGN) shares were flat.",
      "url": "https://finnhub.io/api/news?id=99046c8274aa789d04e09d8a21c51007ce952638b6c31812c698431afcdfc302"
    }
  },
  {
    "ts": null,
    "headline": "Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes",
    "summary": "Ocular Therapeutix shares tumble after Axpaxli wet AMD trial data disappoints investors, despite meeting key Phase 3 goals.",
    "url": "https://finnhub.io/api/news?id=c5bbb4075a770e729f52ec2aaa265543361f0cdd83189d428a7d761ed86165a6",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771323340,
      "headline": "Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes",
      "id": 139122994,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/17/Close-up-Of-A-Womans-Eyes.jpeg?width=2048&height=1536",
      "related": "REGN",
      "source": "Benzinga",
      "summary": "Ocular Therapeutix shares tumble after Axpaxli wet AMD trial data disappoints investors, despite meeting key Phase 3 goals.",
      "url": "https://finnhub.io/api/news?id=c5bbb4075a770e729f52ec2aaa265543361f0cdd83189d428a7d761ed86165a6"
    }
  }
]